



CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.
Manufacturer of Condoms

May 29, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Subject: **Submission of Integrated Filing (Financial) for the Half Year and Year ended 31ST March 2026**

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to Regulation 10(1A) of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFDPoD-2/CIR/P/2024/185 dated December 31, 2024, NSE Circular No. NSE/CML/2025/20 dated April 02, 2025, read with NSE/CML/2025/02 dated January 02, 2025 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, we are submitting herewith the Integrated Filing (Financial) of the Company for the half year and year ended 31st March, 2026.

This is for your information and record.

Thanking You,
Yours Truly

For and on behalf of
Anondita Medicare Limited

Bhawna Bisht
Company Secretary and Compliance Officer
Membership No. A70843

Encl:As Above



Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com | accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

General information about company	
Scrip code*	000000
NSE Symbol*	ANONDITA
MSEI Symbol*	NOTLISTED
ISIN*	INE0VTV01012
Name of company	ANONDITA MEDICARE LIMITED
Type of company	SME
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	22-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	16-05-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Half Yearly
Reporting Quarter	Yearly
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Manufacture of Condom
Start date and time of board meeting	22-05-2026 13:00
End date and time of board meeting	22-05-2026 20:30
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2025	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Revenue From Operations		
	Revenue from operations	8331.87	13741.57
	Other income	43.46	84.24
	Total Income	8375.33	13825.81
2	Expenses		
(a)	Cost of materials consumed	2867.91	5221.13
(b)	Purchases of stock-in-trade	1199.61	1364.54
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-500.33	-579.51
(d)	Employee benefit expense	484.75	832.85
(e)	Finance costs	171.45	353.8
(f)	Depreciation and amortisation expense	67.21	108.09
(g)	Other Expenses		
1	Other Expenses	1133.47	1835.95
	Total other expenses	1133.47	1835.95
	Total expenses	5424.07	9136.85
3	Profit before exceptional and extraordinary items and tax		
		2951.26	4688.96
4	Exceptional items	0	0
5	Profit before extraordinary items and tax		
		2951.26	4688.96
6	Extraordinary items	0	0
7	Profit before tax		
		2951.26	4688.96
8	Tax Expense		
	Current tax	653.95	1074.37
	Deferred tax	169.45	184.94
	Total tax expenses	823.4	1259.31
9	Net Profit Loss for the period from continuing operations		
		2127.86	3429.65
10	Profit (loss) from discontinuing operations before tax	0	0
11	Tax expense of discontinuing operations	0	0
12	Net profit (loss) from discontinuing operation after tax		
		0	0
13	Profit (loss) for period before minority interest		
		2127.86	3429.65
14	Share of profit (loss) of associates	0	0
15	Profit (loss) of minority interest	0	0
16	Net profit (Loss) for the period		
		2127.86	3429.65
17	Details of equity share capital		
	Paid-up equity share capital	1808.66	1808.66
	Face value of equity share capital	10	10
	Details of debt securities		
18	Reserves excluding revaluation reserve		11115.06
19	Earnings per equity share (for continuing and discontinued operations)		

	Basic earnings (loss) per share from continuing and discontinued operations	11.38	20.77	
	Diluted earnings (loss) per share from continuing and discontinued operations	11.38	20.77	
20	Debt equity ratio			Textual Information(1)
21	Debt service coverage ratio			Textual Information(2)
22	Interest service coverage ratio			Textual Information(3)
23	Disclosure of notes on financial results			

Statement of Asset and Liabilities		
	Particulars	Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Consolidated
	Equity and liabilities	
1	Shareholders' funds	
	Share capital	1808.66
	Reserves and surplus	11115.06
	Money received against share warrants	
	Total shareholders' funds	12923.72
2	Share application money pending allotment	0
3	Deferred government grants	0
4	Minority interest	203.22
5	Non-current liabilities	
	Long-term borrowings	2387.03
	Deferred tax liabilities (net)	193.52
	Foreign currency monetary item translation difference liability account	0
	Other long-term liabilities	
1		
2		
3		
4		
5		
	Details of other long-term liabilities	
	Total of other long-term liabilities	
	Long-term provisions	17.8
	Total non-current liabilities	2598.35
6	Current liabilities	
	Short-term borrowings	973.12
	Trade Payables	
	(A) Total outstanding dues of micro enterprises and small enterprises	141.23
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	661.56
	Total Trade payable	802.79
	Other current liabilities	
1	Other Current Liabilities	248.78
2		
3		
4		
5		
	Details of other current liabilities	
	Total of other current liabilities	248.78
	Short-term provisions	733.14
	Total current liabilities	2757.83
	Total equity and liabilities	18483.12
	Assets	
1	Non-current assets	
(i)	Property, Plant and Equipment and Intangible assets	
	Property, Plant and Equipment	3909.76

	Producing properties	
	Intangible assets	19.18
	Preproducing properties	
	Property, Plant and Equipment capital work-in-progress	4149.5
	Intangible assets under development or work-in-progress	
	Total Property, Plant and Equipment and Intangible assets	8078.44
(ii)	Non-current investments	331.4
(v)	Deferred tax assets (net)	0.24
(vi)	Foreign currency monetary item translation difference asset account	
(vii)	Long-term loans and advances	220.79
	Other non-current assets	
1	Non Current Asset	0.16
2		
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	0.16
	Total non-current assets	8631.03
2	Current assets	
	Current investments	0
	Inventories	2075.01
	Trade receivables	5185.67
	Cash and cash equivalents	25.24
	Bank balance other than cash and cash equivalents	939.95
	Short-term loans and advances	1114.56
	Other current assets	
1	Other Current Asset	511.66
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	511.66
	Total current assets	9852.09
	Total assets	18483.12
	Disclosure of notes on assets and liabilities	Textual Information(1)

Text Block	
Textual Information(1)	

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-10-2025	01-04-2025
Date of end of reporting period	31-03-2026	31-03-2026
Whether results are audited or unaudited	Audited	Audited
Nature of report standalone or consolidated	Consolidated	Consolidated
1 Segment Revenue		
(net sale/income from each segment should be disclosed)		
1		
Total segment revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other unallocable expenditure net off unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Assets		
Un-allocable Assets		
Net Segment Assets		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		

Cash flow statement - indirect	
Particulars	Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	31-03-2026
Whether results are audited or unaudited	Audited
Nature of report standalone or consolidated	Consolidated
1 Statement of cash flows	
Cash flows from used in operating activities	
Profit before extraordinary items and tax	4688.96
2 Adjustments for reconcile profit (loss)	
Adjustments to profit (loss)	
Adjustments for finance costs	343.15
Adjustments for depreciation and amortisation expense	108.09
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
Adjustments for unrealised foreign exchange losses gains	0
Adjustments for dividend income	0
Adjustments for share-based payments	0
Other adjustments for which cash effects are investing or financing cash flow	0
Other adjustments to reconcile profit (loss)	0
Other adjustments for non-cash items	0.12
Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
Total adjustments to profit (loss)	451.36
3 Adjustments for working capital	
Adjustments for decrease (increase) in inventories	-717
Adjustments for decrease (increase) in trade receivables	-2510.34
Adjustments for decrease (increase) in other current assets	-463.74
Adjustments for increase (decrease) in trade payables	421.26
Adjustments for increase (decrease) in other current liabilities	38.73
Adjustments for provisions	-503.18
Total adjustments for working capital	-3734.27
Total adjustments for reconcile profit (loss)	-3282.91
Net cash flows from (used in) operations	1406.05
Dividends received	0
Interest paid	0
Interest received	0
Income taxes paid (refund)	342.24
Other inflows (outflows) of cash	0
Net cash flows from (used in) operating activities before extraordinary items	1063.81
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) operating activities	1063.81
4 Cash flows from used in investing activities	
Cash flows from losing control of subsidiaries or other businesses	0
Cash flows used in obtaining control of subsidiaries or other businesses	0
Other cash receipts from sales of equity or debt instruments of other entities	0
Other cash payments to acquire equity or debt instruments of other entities	0
Other cash receipts from sales of interests in joint ventures	0
Other cash payments to acquire interests in joint ventures	0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0

	Proceeds from sales of property plant and equipment	0
	Purchase of property plant and equipment	6280.69
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	10.65
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Proceeds from government grants	0
	Net cash flows from (used in) investing activities before extraordinary items	-6270.04
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) investing activities	-6270.04
5	Cash flows from used in financing activities	
	Proceeds from issuing shares	6949.85
	Proceeds from issuing other equity instruments	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	1196.26
	Repayments of borrowings	575.22
	Dividends paid	0
	Interest paid	353.8
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-1088.61
	Net cash flows from (used in) financing activities before extraordinary items	6128.48
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) financing activities	6128.48
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	922.25
6	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	922.25
	Cash and cash equivalents cash flow statement at beginning of period	42.94
	Cash and cash equivalents cash flow statement at end of period	965.19

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Consolidated results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Jain Chopra and Company	Yes	31-03-2029



CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSO CERTIFIED CO.
Manufacturer of Condoms

May 29, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Subject: **Submission of Integrated Filing (Standalone) for the half year and financial year ended March 31, 2026.**

Re: **Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to Regulation 10(1A) of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFDPoD-2/CIR/P/2024/185 dated December 31, 2024, NSE Circular No. NSE/CML/2025/20 dated April 02, 2025, read with NSE/CML/2025/02 dated January 02, 2025 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, we hereby submit the Integrated Filing Standalone Financial Results of the Company for the half year and financial year ended March 31, 2026.

Due to non-functionality of the XBRL utility for generation of the XBRL report, the Company was unable to submit the filing within the prescribed timeline. In this regard, we had intimated the National Stock Exchange of India Limited through email regarding the technical issue. The said issue has been resolved.

Kindly take the aforesaid on your record.

Thanking you,
Yours Truly

**For and on behalf of
Anondita Medicare Limited**

Bhawna Bisht
Company Secretary and Compliance Officer
M No :A70843



Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com | accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

General information about company	
Scrip code*	000000
NSE Symbol*	ANONDITA
MSEI Symbol*	NOTLISTED
ISIN*	INE0VTV01012
Name of company	ANONDITA MEDICARE LIMITED
Type of company	SME
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	22-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	16-05-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Half Yearly
Reporting Quarter	Yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Manufacture of Condoms
Start date and time of board meeting	22-05-2026 13:00
End date and time of board meeting	22-05-2026 20:30
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	01-08-2025
Indicate Company website link for updated RPT policy of the Company	https://anonditamedicare.com/AMLPolicy.php
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes
No. of times funds raised during the quarter	1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
	The Company has not defaulted in payment of Loan and Debt securities or its interest

Financial Results – Other than Bank				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-10-2025	01-04-2025	
Date of end of reporting period		31-03-2026	31-03-2026	
Whether results are audited or unaudited		Audited	Audited	
Nature of report standalone or consolidated		Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Revenue From Operations			
	Revenue from operations	6404.56	11169.62	
	Other income	100.35	175.91	
	Total Income	6504.91	11345.53	
2	Expenses			
(a)	Cost of materials consumed	2867.91	5221.13	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-156.25	-343.19	
(d)	Employee benefit expense	391.93	662.99	
(e)	Finance costs	166.95	348.27	
(f)	Depreciation and amortisation expense	67.09	107.12	
(g)	Other Expenses			
1	Other Expenses	1048.62	1697.84	
	Total other expenses	1048.62	1697.84	
	Total expenses	4386.25	7694.16	
3	Profit before exceptional and extraordinary items and tax	2118.66	3651.37	
4	Exceptional items	0	0	
5	Profit before extraordinary items and tax	2118.66	3651.37	
6	Extraordinary items	0	0	
7	Profit before tax	2118.66	3651.37	
8	Tax Expense			
	Current tax	413.75	784.39	
	Deferred tax	169.47	184.97	
	Total tax expenses	583.22	969.36	
9	Net Profit Loss for the period from continuing operations	1535.44	2682.01	
10	Profit (loss) from discontinuing operations before tax	0	0	
11	Tax expense of discontinuing operations	0	0	
12	Net profit (loss) from discontinuing operation after tax	0	0	
13	Profit (loss) for period before minority interest	1535.44	2682.01	
14	Share of profit (loss) of associates			
15	Profit (loss) of minority interest			
16	Net profit (Loss) for the period	1535.44	2682.01	
17	Details of equity share capital			
	Paid-up equity share capital	1808.66	1808.66	
	Face value of equity share capital	10	10	
	Details of debt securities			
18	Reserves excluding revaluation reserve		9494.38	
19	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	8.49	16.65	
	Diluted earnings (loss) per share from continuing and discontinued operations	8.49	16.65	
20	Debt equity ratio			Textual Information(1)

21	Debt service coverage ratio			Textual Information(2)
22	Interest service coverage ratio			Textual Information(3)
23	Disclosure of notes on financial results			

Statement of Asset and Liabilities		
	Particulars	Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
	Equity and liabilities	
1	Shareholders' funds	
	Share capital	1808.66
	Reserves and surplus	9494.38
	Money received against share warrants	
	Total shareholders' funds	11303.04
2	Share application money pending allotment	0
3	Deferred government grants	
4	Minority interest	
5	Non-current liabilities	
	Long-term borrowings	2359.62
	Deferred tax liabilities (net)	193.52
	Foreign currency monetary item translation difference liability account	
	Other long-term liabilities	
1		
2		
3		
4		
5		
	Details of other long-term liabilities	
	Total of other long-term liabilities	
	Long-term provisions	17.8
	Total non-current liabilities	2570.94
6	Current liabilities	
	Short-term borrowings	967.8
	Trade Payables	
	(A) Total outstanding dues of micro enterprises and small enterprises	141.23
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	652.64
	Total Trade payable	793.87
	Other current liabilities	
1	Other Current Liabilities	193.85
2		
3		
4		
5		
	Details of other current liabilities	
	Total of other current liabilities	193.85
	Short-term provisions	463.62
	Total current liabilities	2419.14
	Total equity and liabilities	16293.12
	Assets	
1	Non-current assets	
(i)	Property, Plant and Equipment and Intangible assets	
	Property, Plant and Equipment	3907.98
	Producing properties	
	Intangible assets	0
	Preproducing properties	
	Property, Plant and Equipment capital work-in-progress	4149.5

	Intangible assets under development or work-in-progress	
	Total Property, Plant and Equipment and Intangible assets	8057.48
(ii)	Non-current investments	351.58
(v)	Deferred tax assets (net)	
(vi)	Foreign currency monetary item translation difference asset account	
(vii)	Long-term loans and advances	220.79
	Other non-current assets	
1	Other Non-current Asset	0.16
2		
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	0.16
	Total non-current assets	8630.01
2	Current assets	
	Current investments	0
	Inventories	1349.14
	Trade receivables	3798.8
	Cash and cash equivalents	21.86
	Bank balance other than cash and cash equivalents	932.24
	Short-term loans and advances	1109.75
	Other current assets	
1	Other Current Asset	451.32
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	451.32
	Total current assets	7663.11
	Total assets	16293.12
	Disclosure of notes on assets and liabilities	Textual Information(1)

Text Block	
Textual Information(1)	

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-10-2025	01-04-2025
Date of end of reporting period	31-03-2026	31-03-2026
Whether results are audited or unaudited	Audited	Audited
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue		
(net sale/income from each segment should be disclosed)		
1		
	Total segment revenue	
	Less: Inter segment revenue	
	Revenue from operations	
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
	Total Profit before tax	
	i. Finance cost	
	ii. Other unallocable expenditure net off unallocable income	
	Profit before tax	
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
	Total Segment Assets	
	Un-allocable Assets	
	Net Segment Assets	
4 Segment Liabilities		
Segment Liabilities		
	Total Segment Liabilities	
	Un-allocable Liabilities	
	Net Segment Liabilities	

Cash flow statement - indirect	
Particulars	Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	31-03-2026
Whether results are audited or unaudited	Audited
Nature of report standalone or consolidated	Standalone
1 Statement of cash flows	
Cash flows from used in operating activities	
Profit before extraordinary items and tax	3651.37
2 Adjustments for reconcile profit (loss)	
Adjustments to profit (loss)	
Adjustments for finance costs	337.62
Adjustments for depreciation and amortisation expense	107.12
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
Adjustments for unrealised foreign exchange losses gains	0
Adjustments for dividend income	0
Adjustments for share-based payments	0
Other adjustments for which cash effects are investing or financing cash flow	0
Other adjustments to reconcile profit (loss)	0
Other adjustments for non-cash items	0.08
Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
Total adjustments to profit (loss)	444.82
3 Adjustments for working capital	
Adjustments for decrease (increase) in inventories	-452.86
Adjustments for decrease (increase) in trade receivables	-2138.37
Adjustments for decrease (increase) in other current assets	-413.08
Adjustments for increase (decrease) in trade payables	441.29
Adjustments for increase (decrease) in other current liabilities	-521.43
Adjustments for provisions	-311.08
Total adjustments for working capital	-3395.53
Total adjustments for reconcile profit (loss)	-2950.71
Net cash flows from (used in) operations	700.66
Dividends received	0
Interest paid	0
Interest received	0
Income taxes paid (refund)	321.79
Other inflows (outflows) of cash	0
Net cash flows from (used in) operating activities before extraordinary items	378.87
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) operating activities	378.87
4 Cash flows from used in investing activities	
Cash flows from losing control of subsidiaries or other businesses	0
Cash flows used in obtaining control of subsidiaries or other businesses	0
Other cash receipts from sales of equity or debt instruments of other entities	0
Other cash payments to acquire equity or debt instruments of other entities	0
Other cash receipts from sales of interests in joint ventures	0
Other cash payments to acquire interests in joint ventures	0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
Proceeds from sales of property plant and equipment	0
Purchase of property plant and equipment	6279.83
Proceeds from sales of intangible assets	0
Purchase of intangible assets	0

Cash advances and loans made to other parties	0
Cash receipts from repayment of advances and loans made to other parties	0
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
Dividends received	0
Interest received	10.65
Income taxes paid (refund)	0
Other inflows (outflows) of cash	127.01
Proceeds from government grants	0
Net cash flows from (used in) investing activities before extraordinary items	-6142.17
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) investing activities	-6142.17
5 Cash flows from used in financing activities	
Proceeds from issuing shares	6949.85
Proceeds from issuing other equity instruments	0
Proceeds from issuing debentures notes bonds etc	0
Proceeds from borrowings	1168.86
Repayments of borrowings	0
Dividends paid	0
Interest paid	348.27
Income taxes paid (refund)	0
Other inflows (outflows) of cash	-1088.6
Net cash flows from (used in) financing activities before extraordinary items	6681.84
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) financing activities	6681.84
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	918.54
6 Effect of exchange rate changes on cash and cash equivalents	
Effect of exchange rate changes on cash and cash equivalents	0
Net increase (decrease) in cash and cash equivalents	918.54
Cash and cash equivalents cash flow statement at beginning of period	35.56
Cash and cash equivalents cash flow statement at end of period	954.1

Format for Disclosure of Related Party Transactions (applicable only for hal

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary							
1	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare Products Private Limited	AANCA1209M	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Renting on Property	99.12	NA			99.12
2	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare Products Private Limited	AANCA1209M	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Security Deposit on Rental Property		NA			0
3	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA5587G	SUBSIDIARY COMPANY	Sale of goods or services		600.53	NA			600.53
4	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA5587G	SUBSIDIARY COMPANY	Loan		442.5	NA			442.5
5	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA5587G	SUBSIDIARY COMPANY	Loan		1518.88	NA			1518.88
6	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA5587G	SUBSIDIARY COMPANY	Interest received		69.19	NA			69.19
7	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare (PARTNERSHIP FIRM)	ABXFA1571G	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Car Rental Services	88.5	NA			88.5
8	Anondita Medicare Limited	ABACA3332M	Anondita Latex Private Limited	AAMCA5889J	ENTITY UNDER COMMON CONTROL PROMOTER	Advance			NA			0
9	Anondita Medicare Limited	ABACA3332M	Anondita Latex Private Limited	AAMCA5889J	ENTITY UNDER COMMON CONTROL PROMOTER	Sale of goods or services			NA			0
10	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare Products Private Limited	AANCA1209M	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Corporate Guarantee Received	374	NA			374
11	Anondita Medicare Limited	ABACA3332M	Anupam Ghosh	AEQPG6875G	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Personal Guarantee Received	400	NA			400
12	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare Products Private Limited	AANCA1209M	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Loan Guarantee Fees	4.41	NA			4.41
13	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare	ABXFA1571G	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Security Deposit for Car Rental Service		NA			0
Total value of transaction												3597.1.

during the
reporting
period

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Jain Chopra and Company	Yes	31-03-2029

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Public Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	28-08-2025
Amount Raised	6949
Report filed for Quarter ended	31-03-2026
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	Infomercs Valuation and Rating Limited
Is there a Deviation / Variation in use of funds raised	Yes
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Yes
If Yes, Date of shareholder Approval	12-02-2026
Explanation for the Deviation / Variation	<p>As disclosed in the Prospectus dated 28 August 2025, the original objects of the issue were Capital Expenditure (CAPEX), Funding Working Capital Requirements, General Corporate Purposes (GCP) and Unidentified Acquisition. During the quarter ended September 30 2025 and December 31 2025 and March 31, 2026, certain modifications and reallocations were made in the utilization of IPO proceeds. Subsequently, the shareholders approved and ratified the revised utilization and reallocation of funds through a Special Resolution passed at the Extra-Ordinary General Meeting of the Members held on 12 February 2026. Accordingly:</p> <ul style="list-style-type: none"> • An amount of 278.41 lakhs was reallocated from General Corporate Purposes to Funding Working Capital Requirements, resulting in the revised allocation for working capital requirements increasing from 3500 Lakhs to 3778.41 Lakhs. • The allocation towards General Corporate Purposes and Unidentified Acquisition was revised from 2015.87 Lakhs to 1737.46 Lakhs and shall now be utilized only towards General Corporate Purposes within the revised regulatory limits. No unidentified acquisition shall be undertaken using the IPO proceeds. • The Company has also revised the deployment timeline of funds under General Corporate Purposes. The entire balance amount was originally expected to be utilized within FY 2025–26; however, the remaining balance of 123.25 Lakhs shall now be utilized during FY 2026–27. • Further, the utilization towards working capital requirements increased due to expansion in the scale of operations and higher working capital needs. The original estimates were based on a projected turnover of 10,000 Lakhs for FY 2025–26, which was revised to approximately 14,500 Lakhs. • There is no material variation in the Capital Expenditure object except changes and/or additions to vendors, as disclosed in the Prospectus.
Comments of the Audit Committee after review	
Comments of the auditors, if any	

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Capex	No variation in object of the issue except changes and/or additions to vendors, as disclosed in the Prospectus	600	0	262.1	0	
2	Funding Working Capital Requirements	Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, an amount of Allocation of 278.41 Lacs out of Object 3 (i.e., General Corporate Purposes) towards funding the Company's working capital requirements, including working capital loans and Cash Credit (CC) limits and with this reallocation, the revised total allocation for working capital now stands at 3,778.41 Lacs. Furthermore, utilization under this object has exceeded the originally estimated utilization during financial year 2025-26 and 2026-27 due to the Company's expanded scale of operations and higher working capital requirements and the working capital estimates were initially based on a projected turnover of 100 crore for FY 2025-26, which has now been revised to approximately 145 crore.	3500	3778.41	3575.55	0	
3	General Corporate Purpose (GCP) 1. for Unidentified Acquisition 2. For GCP (Capped at 25% of gross issue size)	Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, the funds allocated for Object 3 (Unidentified Acquisition and General Corporate Purposes) will to be utilized for GCP only, now restricted to 25% of the total IPO proceeds. Any amount excess of GCP Limit will be transferred towards meeting the Company's working capital requirements. No unidentified acquisition will be undertaken using the IPO proceeds. Furthermore, the allocation of 278.41 Lacs from Object 3 to Object 2 for funding the Company's working capital requirements, including working capital loans and Cash Credit Limit. With this reallocation, the revised total allocation for General Corporate Purposes stands at 1,737.46 Lacs. Further, while the utilization of these funds was initially projected over FY 2025-26 and FY 2026-27, it was subsequently expected that the entire allocation would be deployed within FY 2025-26. However, the balance amount shall now be utilized during the current financial year 2026-27.	2015.87	1737.46	1614.21	0	

Signatory Details	
Name of signatory	Anupam Ghosh
Designation of person	Managing Director
Place	Noida
Date	22-05-2026

